Fully Automatic MRI-Based Hippocampus Volumetry Using FSL-FIRST: Intra-Scanner Test-Retest Stability, Inter-Field Strength Variability, and Performance as Enrichment Biomarker for Clinical Trials Using Prodromal Target Populations at Risk for Alzheimer's Disease

Cavedo Enrica; Suppa Per; Lange Catharina; Opfer Roland; Lista Simone; Galluzzi Samantha; Schwarz Adam J.; Spies Lothar; Buchert Ralph; Hampel Harald

首页> 外文期刊>Journal of Alzheimer's disease: JAD >Fully Automatic MRI-Based Hippocampus Volumetry Using FSL-FIRST: Intra-Scanner Test-Retest Stability, Inter-Field Strength Variability, and Performance as Enrichment Biomarker for Clinical Trials Using Prodromal Target Populations at Risk for Alzheimer's Disease

【24h】

Fully Automatic MRI-Based Hippocampus Volumetry Using FSL-FIRST: Intra-Scanner Test-Retest Stability, Inter-Field Strength Variability, and Performance as Enrichment Biomarker for Clinical Trials Using Prodromal Target Populations at Risk for Alzheimer's Disease

机译：基于FSL-1的全自动MRI基海马体积：扫描仪内部试验 - 标准稳定性，野外强度变异性和性能作为富集生物标志物，用于使用前植物疾病风险的临床试验进行临床试验

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

Background: MRI-based hippocampus volume is a core clinical biomarker for identification of Alzheimer's disease (AD).

机译：背景：基于MRI的海马体积是核心临床生物标志物，用于鉴定阿尔茨海默病（AD）。

著录项

来源
《Journal of Alzheimer's disease: JAD》 |2017年第1期|共14页
作者
Cavedo Enrica; Suppa Per; Lange Catharina; Opfer Roland; Lista Simone; Galluzzi Samantha; Schwarz Adam J.; Spies Lothar; Buchert Ralph; Hampel Harald;
展开▼
作者单位

Univ Pierre &

Marie Curie UPMC Paris 06 Sorbonne Univ Dept Neurol CNRS IM2A INSERM AXA Res Fund &

Charite Univ Med Berlin Dept Nucl Med Berlin Germany;

Charite Univ Med Berlin Dept Nucl Med Berlin Germany;

Jung Diagnost GmbH Hamburg Germany;

Univ Pierre &

Marie Curie UPMC Paris 06 Sorbonne Univ Dept Neurol CNRS IM2A INSERM AXA Res Fund &

IRCCS Ctr San Giovanni Dio Brescia Italy;

Eli Lilly &

Co Indianapolis IN 46285 USA;

Jung Diagnost GmbH Hamburg Germany;

Charite Univ Med Berlin Dept Nucl Med Berlin Germany;

Univ Pierre &

Marie Curie UPMC Paris 06 Sorbonne Univ Dept Neurol CNRS IM2A INSERM AXA Res Fund &

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类神经病学与精神病学;
关键词
Alzheimer's disease; clinical trials; FSL-FIRST; hippocampus; mild cognitive impairment; reproducibility; test/retest;

机译：阿尔茨海默病;临床试验;FSL-First;海马;轻度认知障碍;再现性;测试/重新测试;

相似文献

外文文献

1. Fully Automatic MRI-Based Hippocampus Volumetry Using FSL-FIRST: Intra-Scanner Test-Retest Stability, Inter-Field Strength Variability, and Performance as Enrichment Biomarker for Clinical Trials Using Prodromal Target Populations at Risk for Alzheimer's Disease [J] . Cavedo Enrica, Suppa Per, Lange Catharina, Journal of Alzheimer's disease: JAD . 2017,第1期

机译：基于FSL-1的全自动MRI基海马体积：扫描仪内部试验 - 标准稳定性，野外强度变异性和性能作为富集生物标志物，用于使用前植物疾病风险的临床试验进行临床试验
2. Steps to standardization and validation of hippocampal volumetry as a biomarker in clinical trials and diagnostic criterion for Alzheimer's disease. [J] . Jack CR Jr, Barkhof F, Bernstein MA, Alzheimer’s & dementia: the journal of the Alzheimer’s Association . 2011,第4期

机译：在临床试验和阿尔茨海默氏病诊断标准中，将海马容积作为生物标志物进行标准化和验证的步骤。
3. Requiring an amyloid-beta1-42 biomarker for prodromal Alzheimer's disease or mild cognitive impairment does not lead to more efficient clinical trials. [J] . Donohue MC, Gamst AC, Aisen PS Alzheimer’s & dementia: the journal of the Alzheimer’s Association . 2011,第2期

机译：对于前驱性阿尔茨海默氏病或轻度认知障碍，需要淀粉样蛋白-β1-42生物标志物不会导致更有效的临床试验。
4. Steps to standardization and validation of hippocampal volumetry as a biomarker in clinical trials and diagnostic criteria for Alzheimer’s disease [O] . Clifford R Jack Jr., Frederik Barkhof, Matt A Bernstein, -1

机译：海马体积标准化和验证的步骤作为临床试验中的生物标志物和阿尔茨海默病的诊断标准
5. Requiring an amyloid-beta(1-42) biomarker for prodromal Alzheimer's disease or mild cognitive impairment does not lead to more efficient clinical trials [O] . Schneider, L.S., Kennedy, R.E., Cutter, G.R., 2010

机译：对于前驱性阿尔茨海默氏病或轻度认知障碍，需要淀粉样蛋白β（1-42）生物标志物不会导致更有效的临床试验

Fully Automatic MRI-Based Hippocampus Volumetry Using FSL-FIRST: Intra-Scanner Test-Retest Stability, Inter-Field Strength Variability, and Performance as Enrichment Biomarker for Clinical Trials Using Prodromal Target Populations at Risk for Alzheimer's Disease

摘要

著录项

相似文献

相关主题

期刊订阅